Antacids decrease rilzabrutinib exposure due to pH-dependent solubility. Administer WAYRILZ at least 2 hours before antacids.
Source: NLP:rilzabrutinib
Brand names: Wayrilz
Kinase Inhibitor · Bruton's Tyrosine Kinase Inhibitors · Cytochrome P450 3A Inhibitors · P-Glycoprotein Inhibitors · Breast Cancer Resistance Protein Inhibitors · Organic Anion Transporting Polypeptide 1B1 Inhibitors · Organic Anion Transporting Polypeptide 1B3 Inhibitors · Bile Salt Export Pump Inhibitors
Route: Oral
Contraindications
4 CONTRAINDICATIONS None None
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary Based on animal data, WAYRILZ may cause fetal harm when administered to a pregnant woman. In animal reproduction studies, oral administration of rilzabrutinib to pregnant rats and rabbits during organogenesis at exposures 4- to 10-times the human exposure (based on AUC) at the maximum recommended human dose (MRHD) of 400 mg twice daily did not cause adverse developmental effects. However, adverse visceral and skeletal findings occurred in rat fetuses at a maternally toxic dose at exposures 22-times the human exposure (based on AUC) at the MRHD ( see Data ). There are no available clinical data on the use of WAYRILZ during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, and other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Rilzabrutinib given to pregnant rats by oral gavage at 50, 150 or 300 mg/kg/day during the period of organogenesis (gestation day 7 to 17) did not cause adverse effects on embryo-fetal development at exposures approximately 10-times the clinical exposure at the maximum recommended human dose (MRHD), based on AUC. Increased incidence of post-implantation loss (25%), delayed ossification associated with a markedly lower (24%) mean fetal weight, and increased skeletal (scoliosis) and visceral malformations (abnormalities of major vessels, urogenital tract, and kidney) occurred in a preliminary study in rats at a maternally toxic dose of 500 mg/kg/day that resulted in exposures 22-times the clinical exposure at the MRHD, based on AUC. Rilzabrutinib given to preg
6 interactions on record
Antacids decrease rilzabrutinib exposure due to pH-dependent solubility. Administer WAYRILZ at least 2 hours before antacids.
Source: NLP:rilzabrutinib
Grapefruit is a moderate CYP3A inhibitor. Concomitant use increases rilzabrutinib exposure and risk of adverse reactions.
Source: NLP:rilzabrutinib
H2 receptor antagonists decrease rilzabrutinib exposure due to pH-dependent solubility. Administer WAYRILZ at least 2 hours before these agents.
Source: NLP:rilzabrutinib
Proton pump inhibitors decrease rilzabrutinib exposure due to pH-dependent solubility, potentially reducing efficacy. Avoid concomitant use.
Source: NLP:rilzabrutinib
Seville oranges are strong CYP3A inhibitors. Concomitant use increases rilzabrutinib exposure and risk of adverse reactions.
Source: NLP:rilzabrutinib
Starfruit is a moderate CYP3A inhibitor. Concomitant use increases rilzabrutinib exposure and risk of adverse reactions.
Source: NLP:rilzabrutinib